tetano
Editor, Senior Moderator
Viruses. 2019 Sep 8;11(9). pii: E835. doi: 10.3390/v11090835.
[h=1]Brevilin A, a Sesquiterpene Lactone, Inhibits the Replication of Influenza A Virus In Vitro and In Vivo.[/h] Zhang X[SUP]1[/SUP], Xia Y[SUP]2[/SUP], Yang L[SUP]2[/SUP], He J[SUP]3[/SUP], Li Y[SUP]4[/SUP], Xia C[SUP]5[/SUP].
[h=3]Author information[/h] 1 Department of Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou 510632, Guangdong, China. xiaolizhang@jnu.edu.cn. 2 Department of Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou 510632, Guangdong, China. 3 Institute of Laboratory Animal Science, Jinan University, Guangzhou 510632, Guangdong, China. 4 Institute of Traditional Chinese Medicine and Natural Products, Jinan University, Guangzhou 510632, Guangdong, China. 5 Department of Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou 510632, Guangdong, China. xiachuan@jnu.edu.cn.
[h=3]Abstract[/h] With the emergence of drug-resistant strains of influenza A viruses (IAV), new antivirals are needed to supplement the existing counter measures against IAV infection. We have previously shown that brevilin A, a sesquiterpene lactone isolated from C. minima, suppresses the infection of influenza A/PR/8/34 (H1N1) in vitro. Here, we further investigate the antiviral activity and mode of action of brevilin A against different IAV subtypes. Brevilin A inhibited the replication of influenza A H1N1, H3N2, and H9N2 viruses in vitro. The suppression effect of brevilin A was observed as early as 4-8 hours post infection (hpi). Furthermore, we determined that brevilin A inhibited viral replication in three aspects, including viral RNA (vRNA) synthesis, expression of viral mRNA, and protein encoded from the M and NS segments, and nuclear export of viral ribonucleoproteins (vRNPs). The anti-IAV activity of brevilin A was further confirmed in mice. A delayed time-to-death with 50% surviving up to 14 days post infection was obtained with brevilin A (at a dose of 25 mg/kg) treated animals compared to the control cohorts. Together, these results are encouraging for the exploration of sesquiterpene lactones with similar structure to brevilin A as potential anti-influenza therapies.
[h=4]KEYWORDS:[/h] antiviral; brevilin A; influenza A virus; replication; sesquiterpene lactone
PMID: 31500389 DOI: 10.3390/v11090835
Free full text
[h=1]Brevilin A, a Sesquiterpene Lactone, Inhibits the Replication of Influenza A Virus In Vitro and In Vivo.[/h] Zhang X[SUP]1[/SUP], Xia Y[SUP]2[/SUP], Yang L[SUP]2[/SUP], He J[SUP]3[/SUP], Li Y[SUP]4[/SUP], Xia C[SUP]5[/SUP].
[h=3]Author information[/h] 1 Department of Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou 510632, Guangdong, China. xiaolizhang@jnu.edu.cn. 2 Department of Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou 510632, Guangdong, China. 3 Institute of Laboratory Animal Science, Jinan University, Guangzhou 510632, Guangdong, China. 4 Institute of Traditional Chinese Medicine and Natural Products, Jinan University, Guangzhou 510632, Guangdong, China. 5 Department of Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou 510632, Guangdong, China. xiachuan@jnu.edu.cn.
[h=3]Abstract[/h] With the emergence of drug-resistant strains of influenza A viruses (IAV), new antivirals are needed to supplement the existing counter measures against IAV infection. We have previously shown that brevilin A, a sesquiterpene lactone isolated from C. minima, suppresses the infection of influenza A/PR/8/34 (H1N1) in vitro. Here, we further investigate the antiviral activity and mode of action of brevilin A against different IAV subtypes. Brevilin A inhibited the replication of influenza A H1N1, H3N2, and H9N2 viruses in vitro. The suppression effect of brevilin A was observed as early as 4-8 hours post infection (hpi). Furthermore, we determined that brevilin A inhibited viral replication in three aspects, including viral RNA (vRNA) synthesis, expression of viral mRNA, and protein encoded from the M and NS segments, and nuclear export of viral ribonucleoproteins (vRNPs). The anti-IAV activity of brevilin A was further confirmed in mice. A delayed time-to-death with 50% surviving up to 14 days post infection was obtained with brevilin A (at a dose of 25 mg/kg) treated animals compared to the control cohorts. Together, these results are encouraging for the exploration of sesquiterpene lactones with similar structure to brevilin A as potential anti-influenza therapies.
[h=4]KEYWORDS:[/h] antiviral; brevilin A; influenza A virus; replication; sesquiterpene lactone
PMID: 31500389 DOI: 10.3390/v11090835
Free full text